Rate My Professor Veysel Kayser

His research focuses on biopharmaceutical formulation development, particularly for therapeutic monoclonal antibodies, biosimilars, and biobetters such as aggregation-resistant monoclonal antibodies and antibody-drug conjugates. Additional interests include protein folding and aggregation mechanisms, stabilization and novel formulations for biologics and vaccines targeting influenza, rabies, and other pathogens, as well as nanoparticle-antibody complexes and molecular engineering for biotherapeutics. Kayser coordinates teaching in Pharmaceutics and Formulation Science, covering dosage forms, drug delivery, physicochemical properties, medically relevant viruses, vaccines, biologics, stability of medicines, and analytical methods. He supervises PhD and Honours students and has collaborated with pharmaceutical companies including Sanofi-Pasteur. Key contributions include six patents, such as WO2023/205843 for targeted cancer therapy using bispecific nanoconjugates, and editing two books: Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers (2021) and Monoclonal Antibody-Directed Therapy (2022), along with four book chapters. He has authored over 50 peer-reviewed publications, including Design of therapeutic proteins with enhanced stability (PNAS, 2009), Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding (mAbs, 2011), An Overview of Influenza Viruses and Vaccines (Vaccines, 2021), Ionic liquids as stabilisers of therapeutic protein formulations (2024), and A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC (2025). Kayser serves on editorial boards of journals and has delivered over 100 talks on biologics and vaccines.